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Abstract
Background Since the turn of the last century, the prospect of
head transplantation has captured the imagination of scientists
and the general public. Recently, head transplant has regained
attention in popular media, as neurosurgeons have proposed
performing this procedure in 2017. Given the potential impact
of such a procedure, we were interested in learning the history
of the technical hurdles that need to be overcome, and deter-
mine if it is even technically possible to perform such a pro-
cedure on humans today.
Method We conducted a historical review of available litera-
ture on the technical challenges and developments of head
transplantation. The many social, psychological, ethical, reli-
gious, cultural, and legal questions of head transplantation
were beyond the scope of this review.
Results Our historical review identified the following impor-
tant technical considerations related to performing a head
transplant: maintenance of blood flow to an isolated brain
via vessel anastomosis; availability of immunosuppressive
agents; spinal anastomosis and fusion following cord transfec-
tion; pain control in the recipient. Several animal studies have
demonstrated success in maintaining recipient cerebral perfu-
sion and achieving immunosuppression. However, there is
currently sparse evidence in favor of successful spinal
anastomosis and fusion after transection. While recent publi-
cations by an Italian group offer novel approaches to this
challenge, research on this topic has been sparse and hinges
on procedures performed in animal models in the 1970s. How
transferrable these older methods are to the human nervous
system is unclear and warrants further exploration.
Conclusions Our review identified several important con-
siderations related to performing a viable head trans-
plantation. Besides the technical challenges that remain,
there are important ethical issues to consider, such as
exploitation of vulnerable patients and informed con-
sent. Thus, besides the remaining technical challenges,
these ethical issues will also need to be addressed be-
fore moving these studies to the clinic.
Keywords Head transplantation . Spinal cord fusion . Brain
transplant . Cephalosomatic anastomosis
Introduction
Ever since the beginning of the last century, with advances in
medicine and specifically transplantation, the prospect of head
transplant has captured the imagination of scientists and the
general public. Recently, head transplant has regained atten-
tion in the popular media, as neurosurgeons have proposed to
perform this procedure in the near future.
Given the potential impact of such a procedure, we were
interested in learning the history of various technical hurdles
that need to be overcome, and based on these studies, deter-
mine if it is even technically possible to perform such a pro-
cedure on humans today. To this aim, we present a historical
review of the available literature on the technical challenges
and developments of head transplantation. The many social,
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psychological, ethical, religious, cultural, and legal questions
of head transplantation are beyond the scope of this review.
Methods
Electronic search strategy
We searched PubMed and EMBASE using the following key-
words: Bhead transplant ,^ Bbrain t ransplant ,^ or
Bcephalosomatic anastomosis^ (Tables 1 and 2). The last
search was conducted in June 2016.
Eligibility criteria and study selection
Titles and abstracts of references obtained from the literature
search were screened. We excluded articles written in lan-
guages other than English (n = 3). Inclusion criteria consisted
of any study that described head or brain transplantation. After
title and abstracting screening, remaining articles were read in
full. One author of the team performed full-text screening of
the articles. One senior author verified the final included arti-
cles. Disagreements were solved by discussion. This review
was restricted to published data and was not limited by date of
publication.
Additional papers were included after hand-searching of
the bibliographies of the included papers.
Results
After a thorough search of the literature on the history of head
transplantation, we identified 30 papers describing five tech-
nical challenges relevant for head transplantation (Fig. 1).
Beginning of head transplantation and vessel anastomosis
Ever since the early 1900s, people have discussed the possi-
bility of head transplantation [17, 18]. However, transplanta-
tion surgery at that time faced many challenges.
One of the main challenges in transplant surgery was reli-
able vessel anastomosis.
The challenge faced by vascular surgeons was how to cut
and repair an injured vessel and subsequently restore blood
flow without interrupting circulation. Bone, silver and gold,
and absorbable material grafts were in use in the early 1900s,
but these materials gave uncertain and variable results in pa-
tients [18].
It was French surgeon, Dr. Alexis Carrel, who changed
these results by using a more reliable method of suturing sev-
ered vessels back together: he used fine needles and extremely
thin threads as suture and enlarged the severed vessel opening
using three retaining sutures to form a triangular shape. His
method proved effective in protecting against postoperative
hemorrhages and embolisms, as well as in preventing stric-
tures at the site of the suture [18]. Carrel was able to success-
fully implement this technique to vessel reconstruction and
whole organ transplantation (mainly in procedures involving
the thyroid and kidney) [18].
In 1908, Carrel and American physiologist, Dr. Charles
Guthrie, performed the first dog head transplantation. They
attached one dog’s head onto another dog’s neck, connecting
arteries in such a way that blood flowed first to the decapitated
head and then to the recipient head. The decapitated head was
without blood flow for about 20min, and while the dog dem-
onstrated aural, visual, and cutaneous reflex movements early
after the procedure, its condition soon deteriorated and it was
euthanized after a few hours [9, 11].
While their work in head transplantation was not particu-
larly successful, Carrel and Guthrie made significant contri-
butions to the transplant field’s understanding of vessel anas-
tomosis. In 1912, they were awarded the Nobel Prize in
Physiology and Medicine for their work on limb and organ
transplantation [17].
Another milestone in the history of head transplantation
was reached in the 1950s due to the work of Soviet scientist
and surgeon Dr. Vladmir Demikhov. Like his predecessors,
Carrel and Guthrie, Demikhov made notable contributions to
the field of transplant surgery, especially thoracic surgery. He
improved upon the methods available at the time for maintain-
ing vascular supply during organ transplantation and was able
to perform the first successful coronary bypass surgery in dogs
in 1953. Four dogs survived for more than 2 years after this
surgery [14].
In 1954, Demikhov also attempted a canine head transplant
(Fig. 2). Demikhov’s dogs demonstrated more functional ca-
pacity than Guthrie and Carrel’s dogs and were able to move,
see, and lap up water [9]. A step-by-step documentation of
Demikhov’s protocol published in 1959 reveals how his team
carefully preserved the blood supply to the lung and hearts of
the donor dog:
Table 1 PubMed search string
head transplant[tiab] OR brain transplant[tiab] OR (cephalosomatic[All
Fields] AND anastomosis[All Fields])
Results: 42 hits, 7 June 2016
Table 2 EMBASE search string
‘head’/exp OR head AND transplant.tw OR ‘brain’/exp OR brain AND
transplant.tw OR cephalosomatic AND (‘anastomosis’/exp OR
anastomosis)
Results: 3 hits, 7 June 2016
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First they made an incision at the base of the large dog’s
neck, exposing the jugular vein, the aorta and a segment
of the spinal column. Next they drilled two holes
through the bony part of one vertebra and threaded
two plastic strings, one red and one white, through each
of the holes… Then he and Demikhov, deftly wielding
the scalpel, needle and thread, proceeded with infinite
pains to expose the small blood vessels, drawing a tight
knot of thread around each one in turn as they carved
gradually deeper into Shavka’s vitals. Finally Demikhov
severed the spinal column [16].
Thus, even though the rest of its body had been amputated
from this dog, its head and forepaws still retained and used the
lungs and heart [16, 24]. During the third phase of the trans-
plantation, the main blood vessels of this dog’s head were
connected with the corresponding vessels of the host dog
[16]. The longest that any dog survived this surgery was
29 days, also longer thanGuthrie’s and Carrel’s dogs, but most
died within a few days [9].
This limited survival was mainly due to an immune
response of the recipient to the donor, and the next
major challenge of head transplantation involved the
lack of immunosuppressive agents available at the time
[1, 9]. Without effective ways to manage the immune-
rejection reactions between the donor and recipient,
Demikhov’s work could not be considered in the clini-
cal realm for use in humans [1]. The issue of immuno-
suppression will be addressed below.
In 1965, Robert White, an American neurosurgeon, also
attempted head transplantation.
His goal was to perform a brain transplant onto an isolated
body, contrary to Guthrie and Demikhov, who transplanted the
entire upper body of a dog, and not just the isolated brain [1].
This required him to establish different perfusion tech-
niques than his predecessors.
In fact, maintaining blood flow to an isolated brain was the
biggest challenge for White. He created vascular loops to pre-
serve anastomoses between the internal maxillary and internal
carotid arteries of the donor dog. This system was referred to
as Bauto-perfusion,^ in that it allowed for the brain to be per-
fused by its own carotid system even after being severed at the
second cervical vertebral body [25]. Next, the brain was posi-
tioned between the jugular vein and carotid artery of the re-
cipient [15]. Using these perfusion methods, White was able
to successfully graft six canine brains to the cervical
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Fig. 1 Study selection process
for the identified articles
Fig. 2 Two-headed dog from Demikhov’s experiment. Reprinted from
Konstantinov [14]
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vasculature of six large recipient dogs. The dogs survived
between 6 h and 2 days [25].
By continuous electroencephalogram (EEG) monitoring,
White monitored the viability of the transplanted cerebral tis-
sue and compared the activity of the transplant brain to the
recipient brain. Moreover, using an implantable recording
module, he also kept track of the metabolic state of the brains
via measurements of oxygen and glucose consumption and
demonstrated that the transplanted brains were in a high-
performance metabolic state after surgery, another indication
of functional success of the transplants [25].
Through his auto-perfusion protocol and subsequent track-
ing of brain function, White demonstrated the short-term fea-
sibility of a pure brain, as opposed to upper body, transplant.
White expressed an interest in using these methods to de-
velop a model system whereby he could induce tumor forma-
tion, meningitis, or encephalitis in the brains being
transplanted and subsequently test whether the normal recip-
ient animal’s circulating blood could restore functionality to
injured brains [15].
In 1970,White performed the first cephalic exchange trans-
plantation in primates (Fig. 3). He performed four
cephalosomatic associations between isolated monkey heads
and isolated monkey bodies, employing direct suture of the
carotid and jugular veins. Cervical laminectomy was per-
formed at the level of the fourth through sixth cerebral verte-
brae. Due to the subsequent spinal shock and hypotension
following transection, catecholamine infusion was started
and mechanical pulmonary support initiated and maintained
throughout the remainder of the experiment [15]. Three to four
hours after surgery, each cephalon was able to chew, swallow
food, track with eyes, and bite if orally stimulated [26].
Moreover, through EEGmonitoring, White demonstrated that
these cephalons exhibited a characteristic awake pattern [26].
Despite the aforementioned advances, revascularization in
the cephalon remained a challenge and survival ranged be-
tween 6 and 36 h [26]. Due to constriction that developed in
the jugular vein at the suture line, venous return from the head
was impeded [26]. The direct suture was, therefore, not suc-
cessful enough to allow for unimpeded blood flow, and the
cephalons required continuous infusion with heparin; this
eventually led to blood loss and was a limiting factor in the
longevity of this experiment [26]. Moreover, White acknowl-
edged that the cervical spine transection was another limita-
tion of his methods, as it necessitated the implementation of
continuous respiratory support for the animal [15]. Spinal
transection and cephalon revascularization and ischemia will
be addressed below.
Further modification of optimal vessel anastomoses oc-
curred years later in 2015 by the Chinese surgeon, Xiao-
Ping Ren, [22]. In contrast to the previously described direct
anastomosis, he utilized a method in which only one carotid
artery and the contralateral jugular vein were cut, allowing the
intact carotid artery and jugular vein to continuously perfuse
the donor head throughout the procedure (Fig. 4) [22]. Using
this protocol for head-body transplants in mice, he was able to
maintain the blood pressure of the mice above 100/60 mmHg
during the entire procedure. Moreover, EEG recordings from
both the donor and recipient heads after surgery demonstrated
normal electrical activity [22]. By cutting only one carotid and
jugular vessel, Ren’s method minimized trauma to the recipi-
ent, prevented development of ischemia, and also allowed for
intact brain function [26]. Over half of his mice survived for
periods longer than 24 h, with the longest survival being
6 months [22]. While White’s dog and primate head trans-
plants had demonstrated short-term success, in part due to
complications related to clotting, heparinization, and ische-
mia, Ren’s revascularization protocol allowed for longer-
term survival in mice [22].
Immunosuppression
In 1912, when Guthrie and Carrel were presented with their
Nobel Prize, it was acknowledged that the work they per-
formed Bhad no application in man,^ and that organs
transplanted from one to another will degenerate in their
new owners. While progress had been made in understanding
maintenance of perfusion during transplant surgery, issues like
immunosuppression remained prominent.
In the 1950s and 60s, the face of transplant surgery
changed. The challenge that had been preventing the long-
term success of experiments by Carrel, Guthrie, and
Demikhov had been addressed. Immunosuppressive agents
like azathioprine, 6-mercaptopurine, and corticosteroids were
discovered, and teams of physicians around the world began
to perform human kidney and heart transplants [1].
When White was performing his transplant experiments in
the 1960s and 70s, immunosuppressive agents were now
available.White utilized these drugs in his monkey head trans-
plantations and was able to prevent the occurrence of hyper-
rejection reactions in primates, as demonstrated by histology
of the brain tissue after their death [26]. However, this came at
the cost of extremely high doses of immunosuppression [1,
25]. In fact, the high doses of immunosuppressive agents re-
quired to prevent rejection actually contributed to the death of
White’s monkeys 9 days after transplant.
Early failure ofWhite’smonkeyswas at least in part due to the
toxicity of the high dose of immunosuppressive agents. In addi-
tion, grafts involving the skin posed an additional challenge. Due
to the highly immunogenic nature of skin tissue, transplants in-
volving hands and faces were not responsive to the immunosup-
pressive agents of the time [1]. It was not until 1999 that a
combination of immunosuppressive agents was discovered that
was effective in preventing skin rejection without toxicity if used
in the correct dosages [13]. In particular, lower dose combina-
tions of tacrolimus and mycophenolate mofetil were believed to
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prevent tissue rejection without causing systemic toxicity in the
recipient, representing the ideal balance for skin transplant pa-
tients [13]. Indeed, in 2006, the first human face allograft proved
successful with the use of thymoglobulin, tacrolimus, mycophe-
nolate mofetil, and prednisone [8]. Whether or not the efficacy
and safety of these newer immunosuppressive agents will hold
up in human head transplants, however, remains to be
determined.
Ren [22] has highlighted that it has been particularly difficult
to study immune-rejection in head transplant patients because of
their short-term survival. However, he believes that his cross-
circulation protocol, which extends survival in head transplant
patients, will allow for careful study of immune-mediated rejec-
tion reactions and lead to an understanding of optimal immuno-
suppressive regimens for head transplantation.
Spinal anastomosis
An additional aspect of head transplantation that White and
his predecessors struggled with was the fusion of the donor-
recipient spinal cords. In his study of head transplantation in
primates, White noted that spinal cord severing during the
procedure would ultimately result in the requirement for con-
tinuous respiratory support after transplant [26]. How to suc-
cessfully fuse the donor and recipient spinal cords and allow
for gain of motor function was not addressed until the recent
experiments of Ren and Italian neurosurgeon, Dr. Sergio
Canavero.
In 2014, Ren offered an alternative to the traditional head
transplantation method of transecting the spinal cord. Before
Ren, transection occurred at the C3/C4 level and therefore did
not preserve the brainstem of the donor [20]. Independent
breathing and circulation were lost, and life-support machines
were needed. This was a severe limitation White acknowl-
edged in his primate experiments [26]. In contrast, by
performing mouse head transplants that maintained the integ-
rity of the donor brainstem, Ren’s donor animal could breathe
on its own after transplantation. Ren’s utilization of a transec-
tion site above the brainstem, thereby offered promise for
independent breathing of the donor and longer survival times
compared with the traditional C3/C4 transections performed
by White and those before him [20].
Around the same time as Ren, Canavero also put forth his
own head transplant protocol, BHEAVEN,^ or Head
Fig. 3 From White’s original
paper, showing the isolated
primate cephalon transplanted to
the isolated monkey body via
direct suture of the carotid and
jugular vessels. Reprinted from
White 1971 [26]
Fig. 4 (a) Jugular-carotid cross
circulation in the mouse model of
head transplantation. (b) The first
monkey head transplantation with
cross circulation enacted.
Reprinted from Ren 2016 [21]
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Anastomosis Venture [6]. GEMINI is a component of
BHEAVEN^ that sets it apart from prior models of head trans-
plantation, addressing this very issue of spinal cord integrity.
Canavero’s spinal anastomosis protocol calls for
acute, tightly controlled spinal cord transection, unlike
what occurs during traumatic spinal cord injury [4]. He
posits that a controlled transection will allow for tissue
integrity to be maintained and subsequent recovery and
fusion to occur [6]. Specifically, he highlights how his
protocol will exploit a secondary pathway in the brain,
the cortico-truncoreticulopropriospinal pathway [4]. This
Bpropriospinal interneuronal system,^ first discovered by
Charles Sherrington in the early 1900s, is a gray-matter
system of intrinsic fibers that forms a network of con-
nections between spinal cord segments. When the pri-
mary, corticospinal tract is injured, the severed
corticospinal tract axons can form new connections via
these propriospinal neurons (PNs) [4]. Numerous animal
studies have demonstrated that the propriospinal neurons
act as an Banatomic bridge^ and allow for motor func-
t ion and recovery in animals with a damaged
corticospinal tract [6]. In GEMINI, Canavero plans to
perform a highly controlled transection of the spinal
cord that inflicts minimal damage to the gray matter
[4]. His theory is that the maintenance of these grey
matter PNs will allow for functional recovery to be
achieved after spinal cord transection in humans under-
going a head transplant [4].
A recent review acknowledges a significant role for
propiospinal neurons in recovery after spinal cord injury
[10]. However, this regenerative response of PNs comes from
studies in numerous animal models, including cats, rats, and
mice, which have different spinal cord circuitry and regener-
ative capacities than humans [10]. For example, the authors of
this review describe a classic experiment in which cats
underwent spinal cord transection at the lumbar level.
Remarkably, these spinalized cats were able to recover
weight-bearing hind limb stepping that closely resembled
the normal feline walking pattern [10]. The authors went on
to acknowledge, however, that while many similarities do
exist across species in terms of structural and functional reor-
ganization of sublesional spinal circuits, cats are particularly
plastic in that they are the only mammal species that can
recover walking without extrinsic stimulation of the lumbar
spinal cord [10]. Whether the same regenerative principles
that have been observed in animal models will hold after hu-
man spinal cord transection therefore remains to be elucidated.
It should be noted, however, that similar experiments have
been attempted on primates, as well. In the aforementioned
review, the authors describe one experiment in which primates
underwent incomplete cervical spinal cord injury and, follow-
ing propriospinal neuron-mediated reorganization, were able
to recover significant reaching and digit movements [10].
Still, the authors acknowledge that the precise mechanism
by which PNs lead to Bre-wiring^ after injury remains unclear
[10]. They emphasize that a great deal of research aimed at
understanding the molecular basis and fundamental physiolo-
gy of re-wiring is warranted before the therapeutic potential of
propriospinal circuitry can be truly harnessed [10].
Fusogens
The recent development of Bfusogens^ has also contributed to
progress in the field of spinal anastomosis and recovery.
BFusogens^ refer to polymers, like polyethylene glycol
(PEG), poloxamers, and poloxamines, that have the ability
to fuse the membranes of cells together [10]. In 2004, a team
led by Dr. Richard Borgens at Purdue University treated para-
plegic dogs with PEG injections within 72 h after their spinal
cord injury and found that more than half of the treated dogs
were able to walk within 2 weeks of treatment [2]. Of note,
Borgens himself stated that while the results of his study dem-
onstrated that PEG could offer a clear benefit to dogs with
acute spinal cord injury, there are significant differences be-
tween canine and human spinal cords that must be addressed
before this therapy could reach the human clinical realm [2].
Moreover, Borgens induced spinal cord injury in his model
via a constant displacement compression/crush technique [7].
This type of injury is notably different from the type of tran-
section that would be performed during head transplantation,
and therefore limits the applicability of Borgens’ success with
PEG in the procedure of head transplantation.
In their 2012 review, Cho and Borgens [7] described their
success in applying PEG nanoparticles to guinea pigs with
spinal cord injury. They performed in vivo testing of PEG
application and measured physiological recovery via somato-
sensory evoked potentials (SSEP). Again, they were able to
demonstrate several notable features of PEG as a fusogen,
including its specificity to injured sites, Bsealing^ of disrupted
membranes, reduction in generation of reactive oxygen spe-
cies and lipid peroxidation, and, as mentioned, functional re-
covery as measured by recovery of SSEP conduction [7].
However, as before, the guinea pigs in Cho and Borgens’
study did not experience spinal cord transection; instead the
animals they applied PEG to had been inflicted with a spinal
cord compression injury [7]. Therefore, the success that Cho
and Borgens demonstratedwith respect to the use of PEG after
compression injury is not directly generalizable to the proce-
dure of spinal cord transection, as would occur in head
transplantation.
In his GEMINI protocol, Canavero discussed the afore-
mentioned work of Borgens and Cho in dogs and guinea pigs,
and described his plan to use PEG to reconstitute neural mem-
branes after human spinal cord transection [4, 6]. In addition
to the fact that these animals underwent a compression injury
and did not have their spinal cords transected, another
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limitation of the studies that Canavero relied on is that they
focus on the efficacy of PEG as a fusogen in rats, dogs, or
guinea pigs, with sparse evidence for its use as a spinal cord
fusogen in humans [6]. While a phase-one safety trial using
PEG on uninjured human volunteers has been successfully
completed, further exploration and testing may be warranted
before PEG can be applied to injured humans [4, 7].
In a recent editorial about his GEMINI protocol, Canavero
proposed that in addition to fusogens, electrical stimulation
can also be used to accelerate recovery of the neurons severed
during spinal cord transection [5]. He cited the successful
clinical application of spinal cord stimulation (SCS) in
humans with spinal cord injury [5]. However, one of the stud-
ies he referenced describes three patients with chronic, incom-
plete spinal cord injury who were ambulating with assistive
devices before the stimulation [12]. He also referenced SCS
efficacy in stroke and neural injury rehabilitation. However,
these patient injuries do not mirror those that will follow the
acute spinal cord transection that would occur during a human
head transplantation. Therefore, as with fusogens, further
study should be performed to understand how safe and effec-
tive SCS might be after spinal cord transection in particular.
Revascularization, neuroprotection, cerebral ischemia
As described in the section above on vessel anastomosis, Ren
et al.’s 2015 execution of head transplantations in mice was
successful in maintaining blood flow to the recipient brain
during the entire procedure [20]. The key in this experiment
was that the brain of the recipient animal was perfused by the
blood flow from the carotid artery of the donor animal via a
connection to one of its own carotid arteries (Fig. 2) [21].
Table 3 The technical challenges in performing a safe and viable human head transplant
Technical challenge Successfully
overcome?
Progress to date Remaining issues
Vessel anastomosis Yes • Carrel & Guthrie (1908): improved vessel suturing
techniques
• Demikhov (1954): maintained blood flow to lungs and
heart despite spinal cord transection
• White (1965): auto-perfusion of brain after transection of
cervical body
• Ren et al. (2015): cross-circulation protocol/prevention of
brain ischemia via preservation of one donor carotid and
one donor jugular vessel
Immunosuppression Yes • 1950s and 1960s: development of azathioprine, 6-
mercaptopurine, and corticosteroids
• 1999: discovery of immunosuppressive agents that were
effective in preventing skin rejection without toxicity of
earlier agents





No • Canavero (2013): controlled spinal cord transection to
maintain tissue integrity and allow for functional
recovery
• Ren et al. (2014): spinal cord transection below C3/C4 to
allow for maintenance of brainstem and independent do-
nor breathing
• Based on numerous animal models that do not
duplicate human physiology
• Weak understanding of the propriospinal
circuitry thought to underlie spinal cord
recovery
Spinal cord fusion No • Borgens and Cho (2004-2012): demonstrated success of
Bfusogens,^ like PEG, in spinal cord recovery after injury
• Fusogen efficacy based on animal models (dogs
and guinea pigs); further testing of PEG on
injured humans is warranted
• Injuries to which fusogens applied are not
equivalent to spinal cord transection that would




No • Ren et al. (2015): moderate hypothermia with cross-
circulation approach allows for minimal cerebral ische-
mia
• Putintsev et al. (2008): demonstrated neuroprotective role
of perftoran during periods of cerebral ischemia
• Human head transplantation would require
period of cerebral ischemia greater than that in
mice experiments due to technical obstacles
during surgery
• Efficacy of many potential neuroprotective
pharmacologic agents has not been validated in
clinical settings
Pain control No • Current modalities to address post-operative
central neuropathic pain lack support from
clinical studies; current approaches based on
theory
Acta Neurochir (2016) 158:2239–2247 2245
Furthermore, blood was drained back into the donor internal
jugular vein via the recipient’s own internal jugular vein [21].
This jugular-carotid cross circulation approach allowed for
uninterrupted perfusion of the recipient’s brain tissue and
thereby prevented the development of cerebral ischemia
[21]. When head transplantation is performed in humans,
however, Ren et al. [21] anticipate that there will be a short
period of cerebrovascular arrest due to technical constraints,
such as the physical distance between the gurneys.
Induced hypothermia is a widely used neuroprotective
treatment utilized in patients with cardiac arrest, stroke, and
hypoxic ischemic encephalopathy [21]. In White et al.’s [26]
early experiments in monkeys, he implemented deep hypo-
thermia (<25 °C) to protect the transplanted brain during is-
chemic periods of the procedure. However, in Ren’s model
described above, he was able to successfully carry out a head
transplantation with induction of only moderate hypothermia
in the mice (29-33 °C), a less aggressive temperature than
White et al. had to use [21].
With regards to hypothermia, Ren et al. [21] acknowledged
that the optimal time for cooling has not yet been established.
However, they did not think it would be of concern in their
team’s proposed cephalosomatic anastomosis (CSA) protocol,
since the donor’s brain-dead body would not undergo hypo-
thermia, and the recipient’s body (while it may suffer the com-
plications of hypothermia such as bradycardias, hypotension,
and thrombosis) would be of no consequence since its body
would ultimately be discarded [21].
In addition to hypothermia optimization, there has also
been research exploring pharmacologic agents to preserve
brain function following procedural ischemia [21]. For exam-
ple, perftoran, a gas-transferring fluorinated organic com-
pound, has been used as a blood substitute during hypother-
mia and was demonstrated to offer substantial neuroprotection
andmaintenance of cerebral oxygenation in a randomized trial
of 50 patients [19, 21]. Hydrogen sulfide may also be a can-
didate for use in CSA due to its potential role as a
neuroprotectant gas [21]. However, thus far, no clinical studies
have demonstrated its effectiveness in patients with cerebral
ischemia [21].
Thus, while Ren et al.’s cross circulation and moderate
hypothermia protocol has proven effective in avoiding cere-
bral ischemia in mice head transplantation, further research
into its application on humans, as well as the additional safety
offered by neuroprotective agents, needs to be performed.
Pain control
An issue that was not addressed by early head trans-
plant researchers, likely because they performed experi-
ments on mice and primates, was that of pain. Canavero
et al. [3] published a paper this year that acknowledges
the development of pain as a possible postoperative
complication following head transplantation. They sug-
gest that central neuropathic pain (CCP) could be dealt
with through a selective lesion in the subparietal white
matter that targets the sensory component of chronic
pain [3]. Through high-intensity focused ultrasound,
they believe that they can minimize bleeding, engage
in real-time monitoring, and avoid collateral damage
[3]. This procedure is still very experimental, with no
clinical studies showing that this would actually relieve
symptoms of CCP. Indeed, as the author points out,
further research is warranted before potential application
for chronic post transplant CCP [3].
Future considerations
Head transplantation experiments have been conducted
for over a century, starting with dogs in 1908 and extend-
ing to primate models in the 1970s. Over the past de-
cades, improvements in vascular surgery, immunosuppres-
sive agents, and spinal cord recovery have in some
reignited enthusiasm for potential human head transplants.
Multiple press releases confirm that the author of most of
the recent studies on head transplantation has the intention to
move forward with the first human head transplantation in
December 2017. He was quoted as saying, BWe have already
proved everything we had to prove^ [23].
Our historical review identifies several important con-
siderations related to performing a viable head trans-
plantation, including maintenance of central nervous
system perfusion, spinal anastomosis and fusion, and
pain control (Table 3). Recent publications differ from
earlier publications as they propose techniques that
would allow for maintenance of spinal cord and
brainstem function after transplant, essential for long-
term viability and autonomy of the recipient human.
However, as detailed above, recent research in this field
has been sparse, dominated by a single group, and, in
part, hinges on procedures performed in dogs, mice, and
Rhesus monkeys in the 1970s. How transferrable the
methods of Carrel, Guthrie, Demikhov, White, and co-
workers are to the human nervous system is unclear and
warrants elaborate further exploration before we should
even consider offering humans this procedure. Thus, de-
spite the progress made since the first experiments in
1908, some important technical challenges do remain
(Table 3).
Besides the technical challenges, there are also important
ethical issues to consider before embarking on a procedure
like this. These include questions like: howwould a successful
transplant change the meaning of human identity? While the
literature and media are referring to this procedure as a head
transplantation, it is truly a body transplantation, in which a
person’s brain is receiving a new body. The question then
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becomes: how will patients who emerge from such a life-
changing procedure react to having a new body to control
and associate with their identity? These are complex issues
that warrant further exploration. Besides the technical chal-
lenges, these issues will need to be addressed before
transitioning these studies into clinical practice.
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